Points of integration between the intracellular energy sensor AMP-activated protein kinase (AMPK) activity and the somatotroph axis function

Endocrine

Volumn 42, Issue 2, 2012, Pages 292-298

  Tulipano, Giovanni ^a   Faggi, Lara ^a   Sibilia, Valeria ^b   Giustina, Andrea ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

AMP activated protein kinase; Growth hormone; Pituitary; Pituitary adenomas

Indexed keywords

EVEROLIMUS; FATTY ACID; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; OCTREOTIDE; RAPAMYCIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN;

ACROMEGALY; CALORIC RESTRICTION; CELL GROWTH; CELL PROLIFERATION; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING ADENOMA; GROWTH HORMONE SECRETING CELL; HORMONE SYNTHESIS; HUMAN; HYPOGLYCEMIA; INTRACELLULAR SIGNALING; LIPID OXIDATION; NEGATIVE FEEDBACK; NEUROENDOCRINE TUMOR; NONHUMAN; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; SOMATOSTATIN RELEASE;

EID: 84867398241     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9732-x     Document Type: Review

References (61)

1. D.G. Hardie, AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 8, 774-785 (2007)
2. S.A. Hawley, J. Boudeau, J.L. Reid, K.J. Mustard, L. Udd, T.P. Mäkelä, D.R. Alessi, D.G. Hardie, Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/ beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2, 28 (2003)
3. A. Woods, S.R. Johnstone, K. Dickerson, F.C. Leiper, L.G. Fryer, D. Neumann, U. Schlattner, T. Wallimann, M. Carlson, D. Carling, LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13, 2004-2008 (2003)
4. M.C. Towler, G.D. Hardie, AMP-activated protein kinase in metabolic control and insulin signaling. Circ. Res. 100, 328-341 (2007)
5. S.P. Davies, N.R. Helps, P.T. Cohen, D.G. Hardie, 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C{alpha} and native bovine protein phosphatase-2AC. FEBS Lett. 377, 421-425 (1995)
6. C.T. Lim, B. Kola, M. Korbonits, AMPK as a mediator of hormonal signalling. J. Mol. Endocrinol. 44, 87-97 (2009)
7. S. Sangiao-Alvarellos, L. Varela, M.J. Vazquez, K. Da Boit, S.A. Saha, F. Cordido, C. Dieguez, M. Lopez, Influence of ghrelin and growth hormone deficiency on AMP-activated protein kinase and hypothalamic lipid metabolism. J. Neuroendocrinol. 22, 543-556 (2010)
8. 2+/calmoldulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J. Biol. Chem. 280, 29060-29066 (2005)
9. M. Lu, Q. Tang, J.M. Olefsky, P.L. Mellon, N.J. Webster, Adiponectin activates adenosine monophosphate-activated protein kinase and decreases luteinizing hormone secretion in L(beta)T2 gonadotropes. Mol. Endocrinol. 22, 760-771 (2008)
10. Z. Luo, Y. Zhang, F. Li, J. He, H. Ding, L. Yan, H. Cheng, Resistin induces insulin resistance in both AMPK dependent and AMPK independent mechanisms in HepG2 cells. Endocrine 36, 60-69 (2009)
11. X. Xiao, Y. Dong, J. Zhong, R. Cao, X. Zhao, G. Wen, J. Liu, Adiponectin protects endothelial cells from the damages induced by the intermittent high levels of glucose. Endocrine 40, 386-393 (2011)
12. X.B. Cheng, J.P. Wen, Y. Yang, J. Yang, G. Ning, X.Y. Li, GnRH secretion is inhibited by adiponectin through activation of AMPK-activated protein kinase and extracellular signal-regulated kinase. Endocrine 39, 6-12 (2011)
13. M. Xie, D. Zhang, J.R. Dyck, Y. Li, H. Zhang, M. Morishima, D.L. Mann, G.E. Taffet, A. Baldini, D.S. Khoury, M.D. Schneider, A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc. Natl. Acad. Sci. USA 103, 17378-17383 (2006)
14. A. Suzuki, G. Kusakai, A. Kishimoto, Y. Shimojo, T. Ogura, M.F. Lavin, H. Esumi, IGF-1 phosphorylates AMPK-alpha subunit in ATM-dependent and LKB1-independent manner. Biochem. Biophys. Res. Commun. 324, 986-992 (2004)
15. E. Tomas, T.S. Tsao, A.K. Saha, H.E. Murrey, C. Zhang Cc, S.I. Itani, H.F. Lodish, N.B. Ruderman, Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl- CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc. Natl. Acad. Sci. USA 99, 16309-16313 (2002)
16. W.W. Winder, D.G. Hardie, Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am. J. Physiol. 270, E299-E304 (1996)
17. M.E. Young, G.K. Radda, B. Leighton, Activation of glycogen phosphorylase and glycogenolysis in rat skeletal muscle by AICAR- an activator of AMP-activated protein kinase. FEBS Lett. 382, 43-47 (1996)
18. G.R. Steinberg, S.B. Jorgensen, The AMP-activated protein kinase: role in regulation of skeletal muscle metabolism and insulin sensitivity. Mini-Rev. Med. Chem. 7, 521-528 (2007)
19. V. Locatelli, A. Torsello, Pyruvate and satiety: can we fool the brain? Endocrinology 146, 1-2 (2005)
20. M.F. McCarty, Chronic activation of AMP-activated kinase as a strategy for slowing aging. Med. Hypotheses 63, 334-339 (2004)
21. M.M. Mihaylova, R.J. Shaw, The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 13, 1016-1023 (2011)
22. M. Josie, M. Evans, Metformin and reduced risk of cancer in diabetic patients. Br. Med. J. 330, 1304-1305 (2005)
23. H. Motoshima, B.J. Goldstein, M. Igata, E. Araki, AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J. Physiol. 574, 63-71 (2006)
24. M. Zakikhani, R. Dowling, I.G. Fantus, N. Sonenberg, M. Pollak, Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66, 10269-10273 (2006)
25. T.K. Sengupta, G.M. Leclerc, T.T. Hsieh-Kinser, G.J. Leclerc, I. Singh, J.C. Barredo, Cytotoxic effect of 5-aminoimidazole-4- carboxamide-1-beta-4- ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol. Cancer 6, 46-58 (2007)
26. M. Buzzai, R.G. Jones, R.K. Amaravadi, J.J. Lum, R.J. DeBerardinis, F. Zhao, B. Villet, C.B. Thompson, Systemic treatment with the antidiabetic drug metformin selectively impairs p53- deficient tumor cell growth. Cancer Res. 67, 6745-6752 (2007)
27. H.U. Park, S. Suy, M. Danner, V. Dailey, Y. Zhang, H. Li, D.R. Hyduke, B.T. Collins, G. Gagnon, B. Kallakury, D. Kumar, M.L. Brown, A. Fornace, A. Dritschilo, S.P. Collins, AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol. Cancer Ther. 8, 733-741 (2009)
28. J.M. Corton, J.G. Gillespie, S.A. Hawley, D.G. Hardie, 5-Aminoimidazole- 4-carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229, 558-565 (1995)
29. R. Rattan, S. Giri, A.K. Singh, I. Singh, 5-Aminoimidazole-4- carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J. Biol. Chem. 280, 39582-39593 (2005)
30. Y. Gao, Y. Zhou, A. Xu, D. Wu, Effects of an AMP-activated protein kinase inhibitor, compound C, on adipogenic differentiation of 3T3-L1 cells. Biol. Pharm. Bull. 31, 1716-1722 (2008)
31. I. Kanazawa, T. Yamaguchi, S. Yano, M. Yamauchi, T. Sugimoto, Activation of AMP kinase and inhibition of Rho kinase induce the mineralization of osteoblastic MC3T3E1 cells through endothelial NOS and BMP-2 expression. Am. J. Physiol. Endocrinol. Metab. 296, 139-146 (2009)
32. G. Zhou, R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M.F. Hirshman, L.J. Goodyear, D.E. Moller, Role of AMPK-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174 (2001)
33. E.E. Müller, V. Locatelli, D. Cocchi, Neuroendocrine control of growth hormone secretion. Physiol. Rev. 79, 511-607 (1999)
34. W.B. Wehrenberg, P.J. Bergman, L. Stagg, J. Ndon, A. Giustina, Glucocorticoid inhibition of growth in rats: partial reversal with somatostatin antibodies. Endocrinology 127, 2705-2708 (1990)
35. G. Tulipano, J.E. Taylor, H.A. Halem, R. Datta, J.Z. Dong, M.D. Culler, I. Bianchi, D. Cocchi, A. Giustina, Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125. Pituitary 10, 267-274 (2007)
36. A. Giustina, J.D. Veldhuis, Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr. Rev. 19, 717-797 (1998)
37. A. Giustina, W.B. Wehrenberg, Influence of thyroid hormones on the regulation of growth hormone secretion. Eur. J. Endocrinol. 133, 646-653 (1995)
38. M. Christ-Crain, B. Kola, F. Lolli, C. Fekete, D. Seboek, G. Wittmann, D. Feltrin, S.C. Igreja, S. Ajodha, J. Harvey-White, G. Kunos, B. Müller, F. Pralong, G. Aubert, G. Arnaldi, G. Giacchetti, M. Boscaro, A.B. Grossman, M. Korbonits, AMPactivated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J. 22, 1673-1683 (2008)
39. M. Lopez, R. Lage, A.K. Saha, D. Perez-Tilve, M.J. Vazquez, L. Varela, S. Sangiao-Alvarellos, S. Tovar, K. Raghay, S. Rodriguez- Cuenca, R.M. Deoliveira, T. Castaneda, R. Datta, J.Z. Dong, M. Culler, M.W. Sleeman, C.V. Alvarez, R. Gallego, C.J. Lelliot, D. Carling, M.H. Tschop, C. Dieguez, A. Vidal-Puig, Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab. 7, 389-399 (2008)
40. Z.B. Andrews, Z.W. Liu, N. Wallingford, D.M. Erion, E. Borok, J.M. Friedman, M.H. Tschop, M. Shanabrough, G. Cline, G.I. Shulman, A. Coppola, X.B. Gao, T.L. Horvath, S. Diano, UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. Nature 454, 846-851 (2008)
41. M. Pollak, Insulin and Insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8, 915-928 (2008)
42. I. Chopra, H.F. Li, H. Wang, K.A. Webster, Phosphorylation of the insulin receptor by AMP-activated protein kinase (AMPK) promotes ligand-independent activation of the insulin signalling pathway in rodent muscle. Diabetologia. doi:10.1007/s00125-01 1-2407-y (2012)
43. A.A. Hayashi, C.G. Proud, The rapid inactivation of protein synthesis by growth hormone requires signaling through mTOR. Am. J. Physiol. Endocrinol. Metab. 292, E1647-E1655 (2007)
44. C. Beauloye, A.S. Marsin, L. Bertrand, U. Krause, D.G. Hardie, J.L. Vanoverschelde, L. Hue, Insulin antagonizes AMP-activated protein kinase activation by ischemia or anoxia in rat hearts, without affecting total adenine nucleotides. FEBS Lett. 505, 348-352 (2001)
45. S. Kovacic, C.L. Soltys, A.J. Barr, I. Shiojima, K. Walsh, J.R. Dyck, Akt activity negatively regulates phosphorylation of AMPactivated protein kinase in the heart. J. Biol. Chem. 278, 39422-39427 (2003)
46. K. To, H. Yamaza, T. Komatsu, T. Hayashida, H. Hayashi, H. Toyama, T. Chiba, Y. Higami, I. Shimokawa, Down-regulation of AMP-activated protein kinase by calorie restriction in rat liver. Exp. Gerontol. 42, 1063-1071 (2007)
47. K.A. Al-Regaiey, M.M. Masternak, M. Bonkowski, L. Sun, A. Bartke, Long-lived growth hormone receptor knockout mice: interaction of reduced insulin-like growth factor 1/insulin signaling and caloric restriction. Endocrinology 2005(146), 851-860 (2005)
48. Z. Wang, M.M. Masternak, K.A. Al-Regaiey, A. Bartke, Adipocytokines and the regulation of lipid metabolism in growth hormone transgenic and calorie-restricted mice. Endocrinology 148, 2845-2853 (2007)
49. B. Olsson, Y.M. Bohlooly, S.M. Fitzgerald, F. Frick, A. Ljungberg, B. Ahren, J. Tornell, G. Bergstrom, J. Oscarsson, Bovine growth hormone transgenic mice are resistant to diet-induced obesity but develop hyperphagia, dyslipidemia, and diabetes on a high-fat diet. Endocrinology 146, 920-930 (2005)
50. S. Sangiao-Alvarellos, M.J. Vazquez, L. Varela, R. Nogueiras, A.K. Saha, F. Cordido, M. Lopez, C. Dieguez, Central ghrelin regulates peripheral lipid metabolism in a growth hormoneindependent fashion. Endocrinology 150, 4562-4574 (2009)
51. G. Tulipano, M. Giovannini, M. Spinello, V. Sibilia, A. Giustina, D. Cocchi, AMP-activated protein kinase regulates normal rat somatotroph cell function and growth of rat pituitary adenomatous cells. Pituitary 14, 242-252 (2011)
52. G. Tulipano, D. Soldi, M. Bagnasco, M.D. Culler, J.E. Taylor, D. Cocchi, A. Giustina, Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology 143, 1218-1224 (2002)
53. M.S. Lewitt, Stimulation of IGF-binding protein-1 secretion by AMP-activated protein kinase. Biochem. Biophys. Res. Commun. 282, 1126-1131 (2001)
54. S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina, Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94, 1509-1517 (2009)
55. A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S.W. Lamberts, P.P. Casanueva, P. Trainer, E. Ghigo, K. Ho, S. Melmed, A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95, 3141-3148 (2010)
56. S. Melmed, Acromegaly pathogenesis and treatment. J. Clin. Invest. 119, 3189-3202 (2009)
57. A. Gorshtein, H. Rubinfeld, E. Kendler, M. Theodoropoulou, V. Cerovac, G.K. Stalla, Z.R. Cohen, M. Hadani, I. Shimon, Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GHsecreting pituitary tumor cells in vitro. Endocr. Relat. Cancer 16, 1017-1027 (2009)
58. G. Tulipano, L. Faggi, M. Losa, P. Mortini, M. Spinello, D. Cocchi, A. Giustina, Effects of the combined treatment with AMPK activator and somatostatin-14 on hormone secretion and cell proliferation in cultured GH-secreting pituitary tumor cells, in International Congress of Endocrinology/European congress of Endocrinology 2012, Florence, May 5-9 (2012)
59. O. Ali, S. Banerjee, D.F. Kelly, P.D.K. Lee, Management of type 2 diabetes mellitus associated with pituitary gigantism. Pituitary 10, 359-364 (2007)
60. L. Fontana, The scientific basis of caloric restriction leading to longer life. Curr. Opin. Gastroenterol. 25, 144-150 (2009)
61. A. Bartke, Pleiotropic effects of growth hormone signaling in aging. Trends. Endocrinol. Metab. 22, 437-442 (2011)